botulinum toxin. In some embodiments, the liquid pharmaceutical composition further comprises EDTA or an EDTA analog. In some embodiments, the liquid pharmaceutical composition comprises a histidine buffer. In some embodiments, the pH of the liquid pharmaceutical composition ranges from 5 to 7. In some embodiments, the relative weight amount of L-methionine ranges from about 0.1% to about 0.3%. In some embodiments, the relative weight amount of NAC ranges from about 0.1% to about 0.5%. In some embodiments, the relative weight amount of EDTA ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of trehalose ranges from about 1.0 to about 10%. In some embodiments, the relative weight amount of poloxamer 188 ranges from about 2% to about 5%. In some embodiments, the relative weight amount of polysorbate 20 ranges from about 0.02% to about 0.06%.

[0012] In another aspect, the present disclosure provides a solid pharmaceutical composition comprising a botulinum toxin, trehalose, poloxamer 188 or polysorbate 20, NAC, and EDTA or an EDTA analog. In an alternative embodiment, the solid pharmaceutical composition comprises a botulinum toxin, trehalose, poloxamer 188, and NAC. In an alternative embodiment, the solid pharmaceutical composition comprises a botulinum toxin, trehalose, poloxamer 188 and L-methionine. In some embodiments, the solid pharmaceutical composition further comprises histidine buffer. In some embodiments, the relative weight amount of L-methionine ranges from about 0.1% to about 0.3%. In some embodiments, the relative weight amount of NAC ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of EDTA ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of trehalose ranges from about 1.0 to about 10%. In some embodiments, the relative weight amount of poloxamer 188 ranges from about 0.5% to about 5%. In some embodiments, the relative weight amount of polysorbate 20 ranges from about 0.02% to about 0.06%.

[0012a] In another aspect, the present disclosure provides a liquid pharmaceutical composition comprising: (i) a botulinum toxin; (ii) 0.5-5% (w/w) poloxamer 188; ~~and~~ (iii) 0.1-0.3% (w/w) methionine; and (iv) 1-10% (w/w) trehalose; wherein the composition comprises a buffer, wherein the buffer is histidine, and wherein the pH is from 5-7.

~~**[0012b]** In another aspect, the present disclosure provides a pharmaceutical composition as described herein, wherein the composition does not comprise a sugar or polyalcohol.~~

~~**[0012c]** In another aspect, the present disclosure provides a pharmaceutical composition as described herein for use in therapy of diseases, disorders, and conditions selected from neuromuscular diseases, pain, psychological disorders, urological disorders, inflammation, skin disorders, depression and arrhythmia.~~

~~**[0012d]** In another aspect, the present disclosure provides a use of the pharmaceutical composition as described herein in the manufacture of a medicament for treating, reducing the symptoms, and/or prevention of diseases, disorders, and conditions.~~

~~**[0012e]** In another aspect, the present disclosure provides a method of cosmetic treatment for relief of wrinkles comprising the step of administering the pharmaceutical composition as described herein to a subject in need thereof.~~

DESCRIPTION

[0013] Certain compositions of the present invention provide stable liquid or solid pharmaceutical composition comprising a clostridical toxin active ingredient, a disaccharide, a surfactant and an antioxidant. In certain liquid compositions of the present invention, the disaccharide is optional.

[0014] Certain embodiments also provide methods for the treatment of various diseases, disorders and conditions, including, for example, depression (e.g. major depressive disorder), headache (e.g. migraine, tension headache, and the like), pain, atrial fibrillation, hyperhidrosis, muscle spasticity, cervical dystonia, blepherospasm, overactive bladder (e.g. neurogenic detrusor overactivity, and idiopathic overactive bladder), bladder pain (e.g. interstitial cystitis, bladder pain syndrome), skin conditions (e.g. wrinkles, fine wrinkles, excess sebum production, acne, rosacea), irregularities, and the like using the compositions provided according to aspect of the present invention. Embodiments can include various administration techniques, including, for example, injection, such as

What is claimed is:

1. A liquid pharmaceutical composition comprising:

(i) a botulinum toxin;

(ii) 0.5-5% (w/w) poloxamer 188; ~~and~~

(iii) 0.1-0.3% (w/w) methionine~~.~~; and

(iv) 1-10% (w/w) trehalose;

wherein the composition comprises a buffer, wherein the buffer is histidine, and wherein the pH is from 5-7.

2. The composition according to claim 1, further comprising ~~trehalose~~ NaCl and/or ~~sucrose, and~~ EDTA ; wherein the amounts of NaCl and/or EDTA are optionally ~~NaC1, and optionally EDTA.~~ within the following ranges:

0.1-10% (w/w) NaCl; and/or

0.01-0.1% (w/w) EDTA.

3. The composition according to claim 1 or 2, wherein the relative weight amounts (%, w/w) of trehalose ~~or sucrose~~, poloxamer 188, methionine~~, and optionally NaC1, and optionally EDTA~~ are ~~within the following ranges~~:

~~trehalose or sucrose 1 to 10~~

~~poloxamer 188 0.5 to 5~~

~~methionine 0.1 to 0.3 and optionally~~

~~NaC1 0.1 to 10 and optionally~~

~~EDTA 0.01 to 0.1.~~

	a) trehalose	7 to 9;
	poloxamer 188	3.5 to 4.5;
	methionine	0.15 to 0.25;
and are preferably:	trehalose	8;
	poloxamer 188	4;
	methionine	0.2;

or

	b) trehalose	7 to 9;
	poloxamer 188	0.5 to 0.7;
	methionine	0.15 to 0.25;
and are preferably:	trehalose	8;
	poloxamer 188	0.6;
	methionine	0.2;

or

	c) trehalose	1 to 3;
	poloxamer 188	3.5 to 4.5;
	methionine	0.15 to 0.25;
	NaCl	0.4 to 0.8;
and are preferably:	trehalose	2;
	poloxamer 188	4;
	methionine	0.2;
	NaCl	0.6;

or

	d) trehalose	7 to 9;
	poloxamer 188	3.5 to 4.5;
	methionine	0.15 to 0.25;
	EDTA	0.01 to 0.05;
and are preferably:	trehalose	8;
	poloxamer 188	4;
	methionine	0.2;
	EDTA	0.03.

4. The composition according to any one of claims claim 1-3, wherein the concentration of histidine is 20 mM, and the pH is in the range 5.5-6.

~~The composition according to claim 3, wherein the relative weight amounts (%, w/w) of trehalose, poloxamer 188, methionine, and optionally NaC1, and optionally EDTA are:~~

~~a) trehalose or sucrose 7 to 9~~

~~poloxamer 188 3.5 to 4.5~~

~~methionine 0.15 to 0.25;~~

~~and are preferably trehalose or sucrose 8~~

~~poloxamer 188 4~~

~~methionine 0.2; or~~

~~b) trehalose or sucrose 7 to 9~~

~~poloxamer 188 0.5 to 0.7~~

~~methionine 0.15 to 0.25;~~

~~and are preferably trehalose or sucrose 8~~

~~poloxamer 188 0.6~~

~~methionine 0.2; or~~

~~c) trehalose or sucrose 1 to 3~~

~~poloxamer 188 3.5 to 4.5~~

~~methionine 0.15 to 0.25~~

~~NaC1 0.4 to 0.8;~~

~~and are preferably trehalose or sucrose 2~~

~~poloxamer 188 4~~

~~methionine 0.2~~

~~NaC1 0.6; or~~

~~d) trehalose or sucrose 7 to 9~~

~~poloxamer 188 3.5 to 4.5~~

~~methionine 0.15 to 0.25~~

~~EDTA 0.01 to 0.05;~~

~~and are preferably trehalose or sucrose 8~~

~~poloxamer 188 4~~

~~methionine 0.2~~

~~EDTA 0.03.~~

5. The composition according to any one of claims 1-4,~~previous claim, comprising trehalose.~~ wherein the liquid pharmaceutical composition consists of one or more botulinum

toxins, trehalose, poloxamer 188, methionine, a buffer wherein the buffer is histidine, and optionally NaCl, and optionally EDTA.

6. ~~A pharmaceutical composition according to claim 1, wherein the composition does not comprise a sugar or polyalcohol.~~ The composition according to any one of claims 1-5, comprising no animal-derived protein.

7. The composition according to any one of claims 1-6, comprising ethylene diamine tetraacetic acid sodium salt (EDTA) or an EDTA analog, wherein the relative weight amount (%, w/w) of EDTA optionally ranges from about 0.01 to 0.10.

~~The composition according to claim6, wherein the relative weight amounts (%, w/w) of poloxamer 188, and methionine are within the following ranges:~~

~~poloxamer 188 0.5 to S~~

~~methionine 0.1 to 0.3.~~

~~8. The composition according to claim 7, wherein the relative weight amounts (%, w/w) of~~

~~poloxamer 188, and methionine are:~~

~~poloxamer 188 3.5 to 4.5~~

~~methionine 0.15 to 0.25;~~

~~and are preferably~~

~~poloxamer 188 4~~

~~methionine 0.2.~~

~~9. The composition according to any one of claims 1 - 8, wherein the composition is a liquid composition, wherein the composition preferably comprises a buffer.~~

~~10. The composition according to claim 9, wherein the buffer is histidine, wherein the concentration of histidine is preferably 20 mM, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably in the range 5.5-6.~~

~~11. The composition according to any one of claims 1 – 5, wherein the composition is a solid composition, wherein the composition is preferably lyophilised.~~

~~12. The composition according to claim 11, further comprising a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).~~

~~13. The composition according to any one of claims 1 to 4, wherein the composition is a liquid composition consisting of one or more botulinum toxins, trehalose or sucrose, poloxamer 188, methionine, a buffer, and optionally NaC1, and optionally EDTA.~~

~~14. The composition according to any one of claims 1 to 4, wherein the composition is a solid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, a buffer, and optionally NaC1, and optionally EDTA.~~

~~15. The composition according to any one of claims 1, and 6 to 8, wherein the composition is a liquid composition and consists of one or more botulinum toxins, poloxamer 188, methionine, and a buffer.~~

~~16. The composition according to any previous claim, comprising no animal derived protein.~~

~~17. The composition according to any one of claims 1 to 12, and 16, comprising ethylene diamine tetraacetic acid sodium salt (EDTA) or an EDTA analog.~~

~~18. The composition according to claim 17, wherein the relative weight amount (%, w/w) of~~
~~EDTA ranges from about 0.01 to 0.10.~~

~~19. The pharmaceutical composition of any preceding claim for use in therapy of diseases, disorders, and conditions selected from neuromuscular diseases, pain, psychological disorders, urological disorders, inflammation, skin disorders, depression and arrhythmia.~~

~~20. Use of the pharmaceutical composition of any preceding claim in the manufacture of a medicament for treating, reducing the symptoms, and/or prevention of diseases, disorders, and conditions.~~

~~21. The use of claim 20, wherein the diseases, disorders, and conditions are selected from neuromuscular diseases, pain, psychological disorders, urological disorders, inflammation, and skin disorders.~~

~~22. The use of claim 21, wherein the disorder is depression.~~

~~23. The use of claim 21, wherein the condition is cardiac arrhythmia.~~

~~24. A method of cosmetic treatment for relief of wrinkles comprising the step of administering the pharmaceutical composition of any of claims 1 to 39 to a subject in need thereof.~~